Loading clinical trials...
Loading clinical trials...
Multicenter Retrospective Study of Isoflurane in Refractory and Super-Refractory Status Epilepticus (I-Seizure)
Isoflurane might be used as anticonvulsive therapy in refractory status epilepticus. The aim of the study is to assess the efficiency of Isoflurane in this indication.
Investigators will collect in 4 ICUs the data from consecutive patients hospitalized between january 2016 and january 2023. Included patient were those treated by Isoflurane for refractory status epilepticus.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Ch Bethune Beuvry
Beuvry, France
CHU Brest
Brest, France
GH Sud Ile de France, Hôpital de Melun-Sénart
Melun, France
CH Toulon - Sainte Musse
Toulon, France
Start Date
June 30, 2024
Primary Completion Date
September 22, 2025
Completion Date
September 22, 2025
Last Updated
September 26, 2025
66
ACTUAL participants
Isoflurane
DRUG
Lead Sponsor
Hopital of Melun
NCT06344338
NCT07383779
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07281027